EAM Investors LLC Has $914,000 Holdings in Electromed, Inc. (NYSE:ELMD)

EAM Investors LLC decreased its stake in shares of Electromed, Inc. (NYSE:ELMD) by 5.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 30,927 shares of the company’s stock after selling 1,642 shares during the quarter. EAM Investors LLC’s holdings in Electromed were worth $914,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Ritholtz Wealth Management bought a new position in Electromed during the fourth quarter worth $488,000. Barclays PLC acquired a new position in shares of Electromed during the third quarter valued at about $215,000. State Street Corp boosted its position in shares of Electromed by 14.5% during the 3rd quarter. State Street Corp now owns 22,066 shares of the company’s stock worth $474,000 after purchasing an additional 2,800 shares in the last quarter. IFP Advisors Inc bought a new position in shares of Electromed during the 4th quarter worth about $59,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Electromed by 235.8% in the 4th quarter. Bank of New York Mellon Corp now owns 31,615 shares of the company’s stock valued at $934,000 after buying an additional 22,200 shares during the period. Institutional investors own 40.82% of the company’s stock.

Electromed Trading Down 1.1 %

Electromed stock opened at $22.67 on Thursday. The firm has a market capitalization of $193.99 million, a price-to-earnings ratio of 30.23 and a beta of 0.59. The firm’s fifty day moving average price is $25.62 and its two-hundred day moving average price is $27.27. Electromed, Inc. has a 1-year low of $13.74 and a 1-year high of $35.56.

Electromed announced that its Board of Directors has approved a stock buyback plan on Monday, March 10th that permits the company to repurchase $5.00 million in shares. This repurchase authorization permits the company to buy up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Electromed

In other Electromed news, Director Kathleen Skarvan sold 8,640 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $32.25, for a total transaction of $278,640.00. Following the completion of the sale, the director now directly owns 71,576 shares of the company’s stock, valued at approximately $2,308,326. The trade was a 10.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Andrew Summers sold 50,751 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.30, for a total value of $1,385,502.30. Following the completion of the transaction, the director now owns 65,714 shares in the company, valued at $1,793,992.20. This represents a 43.58 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 133,618 shares of company stock valued at $3,821,636. 14.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. B. Riley started coverage on Electromed in a research note on Thursday, February 20th. They set a “buy” rating and a $38.00 price target on the stock. StockNews.com lowered Electromed from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 28th.

Electromed Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.